Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
E-pub ahead of print

Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Time to Thrombolysis and Long-Term Outcomes in Patients With Acute Ischemic Stroke: A Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac Troponin I and Incident Stroke in European Cohorts: Insights From the BiomarCaRE Project

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Characteristics and Outcomes in Patients With COVID-19 and Acute Ischemic Stroke: The Global COVID-19 Stroke Registry

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Incidence of Ischemic Stroke in Individuals With and Without Aortic Valve Stenosis: A Danish Retrospective Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  • TICH-2 Investigators
Vis graf over relationer

BACKGROUND AND PURPOSE: The computed tomography angiography or contrast-enhanced computed tomography based spot sign has been proposed as a biomarker for identifying on-going hematoma expansion in patients with acute intracerebral hemorrhage. We investigated, if spot-sign positive participants benefit more from tranexamic acid versus placebo as compared to spot-sign negative participants.

METHODS: TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage) was a randomized, placebo-controlled clinical trial recruiting acutely hospitalized participants with intracerebral hemorrhage within 8 hours after symptom onset. Local investigators randomized participants to 2 grams of intravenous tranexamic acid or matching placebo (1:1). All participants underwent computed tomography scan on admission and on day 2 (24±12 hours) after randomization. In this sub group analysis, we included all participants from the main trial population with imaging allowing adjudication of spot sign status.

RESULTS: Of the 2325 TICH-2 participants, 254 (10.9%) had imaging allowing for spot-sign adjudication. Of these participants, 64 (25.2%) were spot-sign positive. Median (interquartile range) time from symptom onset to administration of the intervention was 225.0 (169.0 to 310.0) minutes. The adjusted percent difference in absolute day-2 hematoma volume between participants allocated to tranexamic versus placebo was 3.7% (95% CI, -12.8% to 23.4%) for spot-sign positive and 1.7% (95% CI, -8.4% to 12.8%) for spot-sign negative participants (Pheterogenity=0.85). No difference was observed in significant hematoma progression (dichotomous composite outcome) between participants allocated to tranexamic versus placebo among spot-sign positive (odds ratio, 0.85 [95% CI, 0.29 to 2.46]) and negative (odds ratio, 0.77 [95% CI, 0.41 to 1.45]) participants (Pheterogenity=0.88).

CONCLUSIONS: Data from the TICH-2 trial do not support that admission spot sign status modifies the treatment effect of tranexamic acid versus placebo in patients with acute intracerebral hemorrhage. The results might have been affected by low statistical power as well as treatment delay.

REGISTRATION: URL: http://www.controlled-trials.com; Unique identifier: ISRCTN93732214.

OriginalsprogEngelsk
TidsskriftStroke
Sider (fra-til)STROKEAHA120032426
ISSN0039-2499
DOI
StatusE-pub ahead of print - 18 maj 2021

ID: 66257122